MRK
MERCK & CO INC
(NYSE: MRK)​
Balfour Capital Group Researched Merck and Co Inc (MRK) on December 9th, 2022.
Merck & Co., Inc. is a leading global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of prescription medicines, vaccines, biologic therapies, and animal health products. The company focuses on various therapeutic areas, including cardiovascular conditions, cancer, immune disorders, infectious and respiratory diseases, and diabetes. Additionally, Merck offers animal health products such as vaccines and treatments for livestock and companion animals.
Post Recommendation Price Trend Chart
- We have established a Buy recommendation at $108.75 on December 9th, 2022.​
- Our designated price target stands at $145.00.​
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
View More
ARGUS QUANTITATIVE
Argus Quantitative analyzes energy, commodities, and finance with data analytics.
View More
ARGUS ANALYST
Argus Analyst Notes offers timely investment recommendations, insights.
View More
THOMSON REUTERS
Thomson Reuters delivers global financial, legal, and business information to professionals.
View More
2025 Q1 EARNING REPORT
A Q1 report evaluates company financials for investors
Balfour Capital Group wants to clarify that our recommendation to Buy MERCK & CO INC (MRK)​ is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*
INTC
INTEL CORPORATION
(NASDAQ: INTC)
Balfour Capital Group Researched Intel Corporation on December 12th, 2022.
Intel Corporation is a leading developer of process technology and a major manufacturer of semiconductors. The company designs and develops technology products and components, including microprocessors, chipsets, embedded processors, microcontrollers, and Ethernet products. Intel also offers technologies and solutions such as 5G connectivity, artificial intelligence, cloud computing, data center solutions, Internet of Things, and robotics. Its processors are marketed under brands like Core, Atom, Celeron, Pentium, Xeon, and Movidius.
Post Recommendation Price Trend Chart
- We have established a Buy recommendation at $26.43 on December 12th, 2022.
- Our designated price target stands at $75.00
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
View More
ARGUS QUANTITATIVE
Argus Quantitative analyzes energy, commodities, and finance with data analytics.
View More
ARGUS ANALYST
Argus Analyst Notes offers timely investment recommendations, insights.
View More
THOMSON REUTERS
Thomson Reuters delivers global financial, legal, and business information to professionals.
View More
2025 Q1 EARNING REPORT
A Q1 report evaluates company financials for investors
Balfour Capital Group wants to clarify that our recommendation to Buy Intel Corporation
(INTC) is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*
OXY
OCCIDENTAL PETROLEUM CORP.
(NYSE: OXY)
Balfour Capital Group has issued a buy recommendation
for Occidental Petroleum Corp. Â (OXY) on December 12th, 2022.
Occidental Petroleum Corporation is an American company engaged in hydrocarbon exploration and production, with operations primarily in the United States and the Middle East. The company is also involved in petrochemical manufacturing through its subsidiary, OxyChem, which produces polyvinyl chloride (PVC) resins, chlorine, and sodium hydroxide. Occidental is notable for its significant presence in the Permian Basin, where it is the largest operator and oil producer. Additionally, the company is investing in decarbonization projects, including direct air capture (DAC) technology to remove carbon dioxide from the atmosphere.
Post Recommendation Price Trend Chart
- We have established a Buy recommendation at $56.31 on December 12th, 2022.
- Our designated price target stands at $75.00
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
View More
ARGUS QUANTITATIVE
Argus Quantitative analyzes energy, commodities, and finance with data analytics.
View More
ARGUS ANALYST
Argus Analyst Notes offers timely investment recommendations, insights.
View More
THOMSON REUTERS
Thomson Reuters delivers global financial, legal, and business information to professionals.
View More
2024 Q4 EARNING REPORT
A Q4 report evaluates company financials for investors
Balfour Capital Group wants to clarify that our recommendation to Buy Occidental Petroleum Corp. Â (OXY)Â is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*
PYPL
PAYPAL
(NASDAQ: PYPL)
Balfour Capital Group Researched Paypal (PYPL) on December 14th, 2022.
PayPal Holdings, Inc. is an American multinational financial technology company that operates an online payments system in most countries that support online money transfers. It serves as an electronic alternative to traditional paper methods like checks and money orders. PayPal acts as a payment processor for online vendors, auction sites, and many other commercial users, charging a fee for its services. Established in 1998 as Confinity, it went public in 2002 and became a wholly owned subsidiary of eBay that same year. In 2015, PayPal was spun off as an independent company.
Post Recommendation Price Trend Chart
- We have established a Buy recommendation at $93.44 on December 14th, 2022.
- Our designated price target stands at $110.00
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
View More
ARGUS QUANTITATIVE
Argus Quantitative analyzes energy, commodities, and finance with data analytics.
View More
ARGUS ANALYST
Argus Analyst Notes offers timely investment recommendations, insights.
View More
THOMSON REUTERS
Thomson Reuters delivers global financial, legal, and business information to professionals.
View More
2024 Q4 EARNING REPORT
A Q4 report evaluates company financials for investors
Balfour Capital Group wants to clarify that our recommendation to Buy PAYPAL (PYPL) is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*
PANW
PALO ALTO NETWORKS INC
(NASDAQ:PANW)
Balfour Capital Group Researched Palo Alto Networks Inc (PANW)
on January 4th, 2023.
Palo Alto Networks is a leading cybersecurity company that provides advanced security solutions to enterprises, governments, and service providers worldwide. Their offerings include next-generation firewalls, cloud-based security services, and threat intelligence, all designed to protect organizations from a wide range of cyber threats.
Post Recommendation Price Trend Chart
- We have established a Buy recommendation at $158.64 on January 4th, 2023.
- Our designated price target stands at $415.00
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
View More
ARGUS QUANTITATIVE
Argus Quantitative analyzes energy, commodities, and finance with data analytics
View More
ARGUS ANALYST
Argus Analyst Notes offers timely investment recommendations, insights.
View More
THOMSON REUTERS
Thomson Reuters delivers global financial, legal, and business information to professionals.
View More
2025 Q2 EARNING REPORT
A Q2 report evaluates company financials for investors
Balfour Capital Group wants to clarify that our recommendation to Buy Palo Alto Networks
(PANW) is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*
BABA
ALIBABA GROUP HOLDING LTD
(NYSE:BABA)
Balfour Capital Group has issued a buy recommendation
for Alibaba Group Holding Ltd (BABA) on January 31st, 2023.
Alibaba Group is a Chinese multinational conglomerate specializing in e-commerce, retail, internet, and technology. Founded in 1999, the company operates various businesses, including China commerce, international commerce, local consumer services, logistics, cloud computing, and digital media and entertainment. Its mission is to make it easy to do business anywhere.
Post Recommendation Price Trend Chart
- We have established a Buy recommendation at $67.26 on January 31st, 2023.
- Our designated price target stands at $125.00
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
View More
ARGUS ANALYST
Argus Analyst Notes offers timely investment recommendations, insights.
View More
THOMSON REUTERS
Thomson Reuters delivers global financial, legal, and business information to professionals.
View More
2024 Q4 EARNING REPORT
A Q4 report evaluates company financials for investors
Balfour Capital Group wants to clarify that our recommendation to Buy Alibaba Group Holding Ltd (BABA)Â is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*
REGN
REGENERON PHARMACEUTICALS INC.
(NASDAQ:REGN)
Balfour Capital Group has issued a buy recommendation
for Regeneron Pharmaceuticals Inc. (REGN) on March 14th, 2023.
Regeneron Pharmaceuticals, Inc. is a leading biotechnology company that invents, develops, and commercializes life-transforming medicines for people with serious diseases. Founded in 1988 by Dr. Leonard S. Schleifer, the company has developed numerous FDA-approved treatments and maintains a robust pipeline targeting various conditions, including eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.
Post Recommendation Price Trend Chart
- We have established a Buy recommendation at $774.00 on March 14th, 2023.
- Our designated price target stands at $1350.00
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
View More
ARGUS QUANTITATIVE
Argus Quantitative analyzes energy, commodities, and finance with data analytics
View More
ARGUS ANALYST
Argus Analyst Notes offers timely investment recommendations, insights.
View More
THOMSON REUTERS
Thomson Reuters delivers global financial, legal, and business information to professionals.
View More
2024 Q4 EARNING REPORT
A Q4 report evaluates company financials for investors
Balfour Capital Group wants to clarify that our recommendation to Buy Regeneron Pharmaceuticals Inc. (REGN)Â is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*
NVS
NOVARTIS AG
(NYSE:NVS)
Balfour Capital Group has issued a buy recommendation
for Novartis AG (NVS) on March 17th, 2023.
Novartis AG, based in Basel, Switzerland, is a leading multinational pharmaceutical corporation. Formed in 1996 from the merger of Ciba-Geigy and Sandoz, Novartis produces drugs like Clozaril, Diovan, Gleevec, Ritalin, and Lamisil. It divested its agrochemical business in 2000, forming Syngenta.
Post Recommendation Price Trend Chart
- We have established a Buy recommendation at $92.63 on March 17th, 2023.
- Our designated price target stands at $135.00
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
View More
ARGUS QUANTITATIVE
Argus Quantitative analyzes energy, commodities, and finance with data analytics
View More
ARGUS ANALYST
Argus Analyst Notes offers timely investment recommendations, insights.
View More
2025 Q1 EARNING REPORT
A Q1 report evaluates company financials for investors
Balfour Capital Group wants to clarify that our recommendation to Buy Novartis AGÂ (NVS)Â is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*
LRCX
LAM RESEARCH CORP
(NASDAQ:LRCX)
Balfour Capital Group has issued a buy recommendation
for Lam Research Corp (LRCX) on March 20th, 2023.
Lam Research Corporation, headquartered in Fremont, California, supplies wafer-fabrication equipment and services to the semiconductor industry. Founded in 1980, its products are used in front-end wafer processing for creating semiconductor components and wiring, as well as in back-end wafer-level packaging and MEMSÂ manufacturing.
Post Recommendation Price Trend Chart
- We have established a Buy recommendation at $580.25 on March 20th, 2023.
- Our designated price target stands at $1300.00
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
View More
ARGUS QUANTITATIVE
Argus Quantitative analyzes energy, commodities, and finance with data analytics
View More
ARGUS ANALYST
Argus Analyst Notes offers timely investment recommendations, insights.
View More
THOMSON REUTERS
Thomson Reuters delivers global financial, legal, and business information to professionals.
View More
2025 Q1 EARNING REPORT
A Q1 report evaluates company financials for investors
Balfour Capital Group wants to clarify that our recommendation to Buy Lam Research Corp (LRCX)Â is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*
AVGO
BROADCOM INC
(NASDAQ:AVGO)
Balfour Capital Group Researched Broadcom Inc on March 30th, 2023.
Broadcom Inc. (AVGO) is a global technology leader that designs, develops, and supplies a broad range of semiconductor and infrastructure software solutions. The company’s products serve various markets, including data centers, networking, software, broadband, wireless, storage, and industrial sectors.
Post Recommendation Price Trend Chart
- We have established a Buy recommendation at $63.37 on March 30th, 2023.
- Our designated price target stands at $210.00
Analysts Research
With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.
View More
ARGUS QUANTITATIVE
Argus Quantitative analyzes energy, commodities, and finance with data analytics
View More
ARGUS ANALYST
Argus Analyst Notes offers timely investment recommendations, insights.
View More
THOMSON REUTERS
Thomson Reuters delivers global financial, legal, and business information to professionals.
View More
2025 Q1 EARNING REPORT
A Q1 report evaluates company financials for investors
Balfour Capital Group wants to clarify that our recommendation to Buy BROADCOM INC (AVGO) is based on thorough research conducted by our dedicated teams.
We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.
*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*
